Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. Issue 4 (12th April 2018)

• Record Type: Journal Article
• Authors: Vallejo-Torres, Laura; Pujol, Miquel; Shaw, Evelyn; Wiegand, Irith; Vigo, Joan Miquel; Stoddart, Margaret; Grier, Sally; Gibbs, Julie; Vank, Christiane; Cuperus, Nienke; van den Heuvel, Leo; Eliakim-Raz, Noa; Carratala, Jordi; Vuong, Cuong; MacGowan, Alasdair; Babich, Tanya; Leibovici, Leonard; Addy, Ibironke; Morris, Stephen
• Other Names: author non-byline.; Tancheva Dora author non-byline.; Vatcheva-dobrevska Rossitza author non-byline.; Tsiodras Sotirios author non-byline.; Roilides Emmanuel author non-byline.; Várkonyi Istvan author non-byline.; Bodnár Judit author non-byline.; Farkas Aniko author non-byline.; Paul Mical author non-byline.; Carmeli Yehuda author non-byline.; Mangoni Emanuele Durante author non-byline.; Mussini Cristina author non-byline.; Petrosillo Nicola author non-byline.; Vata Andrei author non-byline.; Hristea Adriana author non-byline.; Origüen Julia author non-byline.; Rodriguez-baño Jesus author non-byline.; ArzuYetkin author non-byline.; Saltoglu Nese author non-byline.
• Is Part Of: BMJ open. Volume 8:Issue 4(2018)
• Publication Date: 2018-04-12
• Subjects: urinary tract infections -- cost of illness -- health economics; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2017-020251
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: Complicated urinary tract infections (cUTIs) impose a high burden on healthcare systems and are a frequent cause of hospitalisation. The aims of this paper are to estimate the cost per episode of patients hospitalised due to cUTI and to explore the factors associated with cUTI-related healthcare costs in eight countries with high prevalence of multidrug resistance (MDR). Design: This is a multinational observational, retrospective study. The mean cost per episode was computed by multiplying the volume of healthcare use for each patient by the unit cost of each item of care and summing across all components. Costs were measured from the hospital perspective. Patient-level regression analyses were used to identify the factors explaining variation in cUTI-related costs. Setting: The study was conducted in 20 hospitals in eight countries with high prevalence of multidrug resistant Gram-negative bacteria (Bulgaria, Greece, Hungary, Israel, Italy, Romania, Spain and Turkey). Participants: Data were obtained from 644 episodes of patients hospitalised due to cUTI. Results: The mean cost per case was €5700, with considerable variation between countries (largest value €7740 in Turkey; lowest value €4028 in Israel), mainly due to differences in length of hospital stay. Factors associated with higher costs per patient were: type of admission, infection source, infection severity, the Charlson comorbidity index and presence of MDR. Conclusions: The mean cost per hospitalised case of cUTI was substantial and varied significantly between countries. A better knowledge of the reasons for variations in length of stays could facilitate a better standardised quality of care for patients with cUTI and allow a more efficient allocation of healthcare resources. Urgent admissions, infections due to an indwelling urinary catheterisation, resulting in septic shock or severe sepsis, in patients with comorbidities and presenting MDR were related to a higher cost.